09.05.2024 – 23:19
mAbxience
Madrid (ots/PRNewswire)
mAbxience, a group of companies majority owned by Fresenius Kabi and partially owned by Insud Pharma, announces the appointment of Jurgen Van Broeck as Managing Director. Jurgen, who has served as Global Commercial Director since June 2023, brings a wealth of experience and a proven track record in the pharmaceutical and biosimilars industry.
Prior to his new role, Jurgen spearheaded mAbxience’s strategic initiatives, overseeing all trading, business development and market access activities. He has played a key role in steering the company’s strategic partnerships and determining the growth trajectory of our CDMO services. Under his leadership, mAbxience has successfully expanded its global presence and continued to excel in providing accessible, high-quality medicines worldwide.
Jurgen comes to mAbxience with nearly two decades of extensive healthcare experience, including significant positions at multinational companies such as Merck and Mundipharma. His expertise has proven particularly useful in launching the first immunological biosimilar in several regions, initiating extensive in- and out-licensing agreements and in managing commercial activities in several regions.
Commenting on his new role, Jurgen said: “I am honored to lead mAbxience during this exciting phase of the company’s growth as we continue to strive for excellence in everything we do. Our goal of providing high quality, affordable biologics and providing world-class CDMO services remains at the core of our strategy. I look forward to working closely with our talented team to advance our pipeline, expand our global footprint and become a globally recognized biologics CDMO.”
mAbxience remains committed to its mission of improving quality of life through universal access to high-quality biopharmaceuticals. With a robust product pipeline and strategic partnerships in more than 100 markets, mAbxience will continue its path as a leading force in the global biopharmaceutical landscape under Jurgen’s leadership.
About mAbxience mAbxience is a Spanish company specializing in the development, production and marketing of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement under which Fresenius Kabi will acquire a majority stake in mAbxience, thereby becoming a global, vertically integrated biotechnology company. Fresenius Kabi is an operating company of the global healthcare group Fresenius.
For more information about mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com) or LinkedIn.
Photo: https://mma.prnewswire.com/media/2408752/Jurgen_Van_Broeck.jpg
View original content: https://www.prnewswire.com/de/pressemitteilungen/mabxience-ernennt-jurgen-van-broeck-zum-neuen-geschaftsfuhrer-302141808.html
Press contact:
Miguel Martínez-Cava,
Global External Communications Manager,
[email protected],
+34 606 59 74 64
Original content by: mAbxience, transmitted by news aktuell